Contract Services Clinical Research
Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Me...
May 14, 2026 | News
Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation Given the accelerating global momentum in CAR-T and gene th...
May 13, 2026 | News
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreement...
May 13, 2026 | News
ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global ...
May 12, 2026 | News
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhala...
May 11, 2026 | News
RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, ...
May 11, 2026 | News
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
May 11, 2026 | News
ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrat...
May 11, 2026 | News
ABEC, a global leader in bioprocess engineering solutions, announced the expansion of its Process Sciences group, expanding its ability to ...
May 08, 2026 | News
Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Kore...
May 08, 2026 | News
New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical productio...
May 05, 2026 | News
EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...
May 05, 2026 | News
– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed a...
May 05, 2026 | Report
Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...
May 04, 2026 | News
Most Read
Bio Jobs
News
Editor Picks